Latest News and Press Releases

Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increaseProduct Revenues in the first in the first...

Alvotech (NASDAQ: ALVO) áætlar að mögulegir tollar á innflutning lyfja til Bandaríkjanna hefðu hverfandi áhrif á tekjur félagsins af sölu lyfja á árinu. Vöruinnflutningur frá Íslandi fellur undir...

Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the...

REYKJAVIK, Iceland, May 07, 2025 (GLOBE NEWSWIRE) --  Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for...

Alvotech's and Teva's SELARSDI™ (ustekinumab-aekn) is now interchangeable with all presentations of the reference biologic Stelara®.

Matvæla- og lyfjastofnun Bandaríkjanna (FDA) hefur heimilað sölu Selarsdi með útskiptileika við frumlyfið við Stelara, fyrir öll lyfjaform og ábendingar frumlyfsins, frá og með 30. apríl sl. Selarsdi...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April...

REYKJAVIK, Iceland, May 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide,...

Alvotech (NASDAQ: ALVO) mun senda út tilkynningu með uppgjöri fyrsta ársfjórðungs 2025 eftir lokun markaða í Bandaríkjunum, miðvikudaginn 7. maí nk. Uppgjörsfundur með greinendum, sem sendur er út í...

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...